Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep293 | Calcium and Vitamin D metabolism | ECE2015

An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1 infected women independently of protease inhibitors therapy

Pepe Jessica , Mezzaroma Ivano , Fantauzzi Alessandra , Falciano Mario , Salotti Alessandra , Di Traglia Mario , Diacinti Daniele , Belcastro Sara , Piemonte Sara , Cipriani Cristiana , Minisola Salvatore

Introduction: The best repletion and maintenance dosing regimens with cholecalciferol in vitamin D deficient HIV-1 patients remain unknown. Protease inhibitors (PIs) have been shown to inhibit vitamin D 1α- and 25α-hydroxylation in hepatocyte and monocyte cultures. We therefore evaluated the effect of a single high dose of cholecalciferol in vitamin D deficient HIV-1 postmenopausal women undergoing treatment with highly Active Anti-Retroviral Therapy (cART), with and...

ea0099rc2.4 | Rapid Communications 2: Calcium and Bone | Part I | ECE2024

Primary hyperparathyroidism in children and adolescents: Clinical features and treatment outcomes from an Italian multicenter study

Cetani Filomena , Della Valentina Simone , Scillitani Alfredo , Dal Lago Anna , Pierotti Laura , Sardella Chiara , Madeo Bruno , Cairoli Elisa , Eller Vainicher Cristina , Procopio Massimo , Barale Marco , Palmieri Serena , Gianotti Laura , Castellano Elena , Lania Andrea , Pitea Marco , Lanzi Roberto , Maggiore Riccardo , Cipriani Cristiana , Pepe Jessica , Corbetta Sabrina

Primary hyperparathyroidism (PHPT) is rare in the pediatric population, with an estimated incidence of 0.5–5 cases per 100,000 person-years in children. Data regarding the clinical phenotype, the surgical outcomes are scarce. The objective of our study was to retrospectively analyze the phenotype of apparently sporadic PHPT in patients ≤21 years in major endocrinology reference centers in Italy. None of the patients had known familial syndromes. A total of 41 patien...

ea0099p450 | Calcium and Bone | ECE2024

A pharmacoeconomic analysis from Italian guidelines for the management of sporadic primary hyperparathyroidism

Attanasio Roberto Samperi Irene , Scoppola Alessandro , Paoletta Agostino , Novizio Roberto , Vescini Fabio , Borretta Giorgio , Chiodini Iacopo , Papini Enrico , Persichetti Agnese , Basile Michele , Boniardi Marco , Carotti Marina , Castellano Elena , Cipriani Cristiana , Eller-Vainicher Cristina , Giannini Sandro , Iacobone Maurizio , Salcuni Antonio/////Stefano , Saponaro Federica , Spiezia Stefano , Versari Annibale , Zavatta Guido , Mitrova Zuzana , Giovannazzi Alexia , Saulle Rosella , Vecchi Simona , Antonini Debora , Calo Giorgio , Cetani Filomena , Cianferotti Luisella , Corbetta Sabrina , De Rimini Maria Luisa , Falchetti Alberto , Iannetti Giovanni , Laureti Stefano , Lombardi Celestino/////Pio , Madeo Bruno , Marcocci Claudio , Mazzaferro Sandro , Miele Vittorio , Minisola Salvatore , Palermo Andrea , Pepe Jessica , Tonzar Laura , Scillitani Alfredo , Grimaldi Franco , Cozzi Renato , Attanasio Roberto

Background: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease and the most frequent cause of hypercalcemia in outpatients with an estimated incidence of 20/100 000/year and prevalence in the general population of 0.1%–0.4%. Parathyroidectomy (PTX) is the only treatment that can achieve PHPT cure but a few medications can be used to control calcium levels, bone and kidney impairment.Aims: 1) To assess costs associated with...